Clinical Trials Logo

Filter by:
NCT ID: NCT00835770 Completed - Clinical trials for Relapsing-Remitting Multiple Sclerosis

BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)

ENDORSE
Start date: February 3, 2009
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test.

NCT ID: NCT00831714 Completed - Clinical trials for Venous Thromboembolism

Xarelto for VTE Prophylaxis After Hip or Knee Arthroplasty

XAMOS
Start date: February 2009
Phase: N/A
Study type: Observational

The main goal is to provide additional information to the risk-benefit assessment of the drug.

NCT ID: NCT00825058 Completed - Clinical trials for Major Depressive Disorders

Efficacy and Safety of SR58611 Compared to Placebo and Paroxetine

Start date: November 2003
Phase: Phase 3
Study type: Interventional

Primary objective : - To demonstrate the antidepressant efficacy on the Hamilton Depression Rating Scale of SR58611A 700mg/day compared with placebo in the treatment of patients with a recurrent major depressive episode. Secondary objectives: - To assess the safety profile of SR58611A 700 mg/d in comparison to placebo and to assess plasma concentrations of the active metabolite.

NCT ID: NCT00824226 Completed - Hypoparathyroidism Clinical Trials

Magnesium Treatment in Hypoparathyroidism

Start date: January 2009
Phase: N/A
Study type: Interventional

Study hypothesis: supplementary magnesium may influence the blood calcium level in treated hypoparathyroid patients. Patients will be treated with supplementary magnesium (350 mg/day) for 3 weeks. Calcium and other relevant blood parameters will be measured before the treatment, at the end of treatment and 2 weeks after stopping treatment.

NCT ID: NCT00813709 Completed - Multiple Sclerosis Clinical Trials

Long-term Follow-Up of Patients Who Participated in Study 27025 (REFLEX)

REFLEXION
Start date: December 2008
Phase: Phase 3
Study type: Interventional

REFLEXION is a double blind extension of the study 27025 (NCT00404352) (REFLEX). The purpose of the study is to obtain long-term follow-up data in subjects with clinically definite multiple sclerosis (MS) and subjects with a first demyelinating event at high risk of converting to MS, treated with fetal bovine serum [FBS]-free/human serum albumin [HSA]-free formulation of interferon [IFN]-beta-1a (RNF).

NCT ID: NCT00811941 Completed - Alcohol Dependence Clinical Trials

Safety and Efficacy of Nalmefene in Patients With Alcohol Dependence

SENSE
Start date: March 2009
Phase: Phase 3
Study type: Interventional

The purpose of the study is long-term safety, tolerability and efficacy of nalmefene in patients with alcohol dependence.

NCT ID: NCT00810199 Completed - Clinical trials for Rheumatoid Arthritis

A Study of Tocilizumab and Methotrexate Treatment Strategies (Adding Tocilizumab to Methotrexate Versus Switching to Tocilizumab) in Patients With Active Rheumatoid Arthritis With Inadequate Response to Prior Methotrexate Treatment

Start date: March 2009
Phase: Phase 3
Study type: Interventional

This 2 arm study will compare 2 treatment strategies based on tocilizumab in combination with methotrexate or placebo in patients with moderate to severe rheumatoid arthritis. Patients receiving methotrexate treatment will be randomized to receive either a) tocilizumab 8 mg intravenous (iv) every 4 weeks + methotrexate orally (po) weekly or b) tocilizumab 8 mg iv every 4 weeks + placebo po weekly. After the first 24 weeks of blinded treatment, treatment adjustments (increase or decrease of treatment intensity) may be introduced at intervals, based on response. The anticipated time on study treatment is up to 3 years, and the target sample size is approximately 470 patients.

NCT ID: NCT00803049 Completed - Multiple Sclerosis Clinical Trials

Long Term Safety and Efficacy Study of Teriflunomide 7 mg or 14 mg in Patients With Relapsing-Remitting Multiple Sclerosis

Start date: October 2006
Phase: Phase 3
Study type: Interventional

The primary objective of this study is to document the long-term safety and tolerability of teriflunomide in Multiple Sclerosis (MS) patients with relapse. The secondary objective is to document the long-term efficacy on disability progression, relapse rate and Magnetic Resonance Imaging (MRI) parameters.

NCT ID: NCT00802178 Completed - Parkinson Disease Clinical Trials

First Presentation of Parkinson Disease Patients to Neurologist

Start date: February 2006
Phase: N/A
Study type: Observational

In this study information is gathered about the treatment of Parkinson patients who present themselves in a neurological practice for the first time

NCT ID: NCT00800332 Completed - Rhinoconjunctivitis Clinical Trials

Dose Finding Study With CYT003-QbG10 in Patients With House Dust Mite Allergy

Start date: November 2008
Phase: Phase 2
Study type: Interventional

The purpose of the study is to test whether vaccinations with CYT003-QbG10 can improve allergy symptoms in patients with house dust mite allergy. The active treatment will be compared against placebo.